

## **Clinical Policy: Palivizumab (Synagis)**

Reference Number: CP.PHAR.16

Effective Date: 08.01.09

Last Review Date: 05.21

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### **Description**

Palivizumab (Synagis<sup>®</sup>) is a recombinant humanized mouse immunoglobulin monoclonal antibody which provides passive immunity against respiratory syncytial virus (RSV).

### **FDA Approved Indication(s)**

Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients:

- With a history of premature birth (less than or equal to 35 weeks gestational age) who are 6 months of age or younger at the beginning of RSV season;
- With bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season;
- With hemodynamically significant congenital heart disease and who are 24 months of age or younger at the beginning of RSV season.

Limitation(s) of use: The safety and efficacy of Synagis have not been established for treatment of RSV disease.

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Synagis is **medically necessary** when the following criteria are met:

#### **I. Initial Approval Criteria**

##### **A. Preterm Infant** (must meet all):

1. Diagnosis of preterm infant with gestational age < 29 weeks;
2. Age at onset of RSV season < 12 months;
3. Request is for RSV prophylaxis;
4. Medical justification supports requests for RSV prophylaxis beyond the identified season duration for Florida or beyond September through May for the remainder of the U.S. (*see Appendix D*);
5. Member has not been hospitalized with RSV disease during the current RSV season;
6. Dose does not exceed 15 mg/kg once a month by intramuscular (IM) administration (*see Appendix E for dose rounding guidelines*).

**Approval duration: up to 5 doses per RSV season**

**B. Chronic Lung Disease of Prematurity** (must meet all):

1. Diagnosis of chronic lung disease (CLD) of prematurity (i.e., BPD) defined as gestational age < 32 weeks and a requirement for > 21% oxygen for ≥ 28 days after birth;
2. Age at onset of RSV season (a or b):
  - a. Age < 12 months;
  - b. Age ≥ 12 months to < 24 months and continues to require supplemental oxygen, chronic systemic corticosteroid therapy, or diuretic therapy within 6 months of the start of the RSV season;
3. Request is for RSV prophylaxis;
4. Medical justification supports requests for RSV prophylaxis extending beyond the identified season duration for Florida or beyond September through May for the remainder of the U.S. (*see Appendix D*);
5. Member has not been hospitalized with RSV disease during the current RSV season;
6. Dose does not exceed 15 mg/kg once a month by IM administration (*see Appendix E for dose rounding guidelines*).

**Approval duration: up to 5 doses per RSV season**

**C. Congenital Heart Disease** (must meet all):

1. Age and diagnosis at onset of RSV season (a or b):
  - a. Age < 12 months and either (i or ii):
    - i. Diagnosis of acyanotic heart disease and either (a or b):
      - a) Receiving medication to control congestive heart failure AND will require a cardiac surgical procedure;
      - b) Diagnosis of moderate to severe pulmonary hypertension;
    - ii. Diagnosis of a cyanotic heart defect and RSV prophylaxis is recommended by a pediatric cardiologist;
  - b. Age < 24 months and undergoing cardiac transplantation or cardio-pulmonary bypass during the current RSV season;
2. Request is for RSV prophylaxis;
3. Medical justification supports requests for RSV prophylaxis extending beyond the identified season duration for Florida or beyond September through May for the remainder of the U.S. (*see Appendix D*);
4. Member has not been hospitalized with RSV disease during the current RSV season;
5. Dose does not exceed 15 mg/kg once a month by IM administration (*see Appendix E for dose rounding guidelines*).

**Approval duration: up to 5 doses per RSV season** (*6 doses if cardio-pulmonary bypass*)

**D. Anatomic Pulmonary Abnormalities, Neuromuscular Disorders, Infants Profoundly Immunocompromised (off-label)** (must meet all):

1. Age and diagnosis at onset of RSV season (a or b):
  - a. Age < 12 months and diagnosis of an anatomic pulmonary abnormality or neuromuscular disorder that impairs the ability to clear secretions from the upper airway (e.g., due to ineffective cough);

- b. Age < 24 months and will be profoundly immunocompromised during the RSV season (e.g., due to solid organ or hematopoietic stem cell transplantation, chemotherapy, severe combined immunodeficiency, chronic granulomatous disease);
2. Request is for RSV prophylaxis;
3. Medical justification supports requests for RSV prophylaxis extending beyond the identified season duration for Florida or beyond September through May for the remainder of the U.S. (see Appendix D);
4. Member has not been hospitalized with RSV disease during the current RSV season;
5. Dose does not exceed 15 mg/kg once a month by IM administration (*see Appendix E for dose rounding guidelines*).

**Approval duration: up to 5 doses per RSV season**

**E. Cystic Fibrosis (off-label) (must meet all):**

1. Diagnosis of cystic fibrosis and one of the following (a or b):
  - a. Clinical evidence of nutritional compromise;
  - b. Diagnosis of CLD of prematurity defined as gestational age < 32 weeks and requirement for > 21% oxygen for ≥ 28 days after birth;
2. Age at onset of RSV season (a or b):
  - a. Age < 12 months;
  - b. Age < 24 months and (i or ii):
    - i. Manifestations of severe lung disease (e.g., previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or chest computed tomography that persist when stable);
    - ii. Weight for length < 10th percentile;
3. Request is for RSV prophylaxis;
4. Medical justification supports requests for RSV prophylaxis extending beyond the identified season duration for Florida or beyond September through May for the remainder of the U.S. (*see Appendix D*);
5. Member has not been hospitalized with RSV disease during the current RSV season;
6. Dose does not exceed 15 mg/kg once a month by IM administration (*see Appendix E for dose rounding guidelines*).

**Approval duration: up to 5 doses per RSV season**

**F. Alaska Native and Other American Indian Infants (off-label) (must meet all):**

1. Medical director consultation is required for requests relating to Alaska native and other American Indian infants that fall outside the criteria outlined above;
2. Alaska native infants: Eligibility for prophylaxis may differ from the remainder of the U.S. on the basis of epidemiology of RSV in Alaska, particularly in remote regions where the burden of RSV disease is significantly greater than in the general U.S. population,
3. Other American Indian infants: Limited information is available concerning the burden of RSV disease among American Indian populations. However, special consideration may be prudent for Navajo and White Mountain Apache infants in the first year of life.
4. Request is for RSV prophylaxis;

5. Medical justification supports requests for RSV prophylaxis extending beyond the identified season duration for Florida or beyond September through May for the remainder of the U.S. (see Appendix D);
6. Member has not been hospitalized with RSV disease during the current RSV season;
7. Dose does not exceed 15 mg/kg once a month by IM administration (*see Appendix E for dose rounding guidelines*).

**Approval duration: up to 5 doses per RSV season**

**G. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. All Indications in Section I (must meet all):**

1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Request is for RSV prophylaxis;
3. Member will not reach 24 months of age at the start of RSV season;
4. Medical justification supports requests for RSV prophylaxis extending beyond the identified season duration for Florida or beyond September through May for the remainder of the U.S. (*see Appendix D*);
5. Member has not yet received 5 Synagis doses in the current RSV season (*6 doses if cardio-pulmonary bypass*);
6. Member has not been hospitalized with RSV disease during the current RSV season;
7. If request is for a dose increase, new dose does not exceed 15 mg/kg once a month by IM administration (*see Appendix E for dose rounding guidelines*).

**Approval duration: up to 5 doses per RSV season (6 doses if cardio-pulmonary bypass)**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.  
**Approval duration: Duration of request or up to 5 doses per RSV season (whichever is less);** or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

BPD: bronchopulmonary dysplasia                      HHS: Health and Human Services  
CLD: chronic lung disease of prematurity            RSV: respiratory syncytial virus  
FDA: Food and Drug Administration

*Appendix B: Therapeutic Alternatives*

Not applicable

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): previous significant hypersensitivity reaction to Synagis
- Boxed warning(s): none reported

*Appendix D: RSV Seasonal Durations across the United States - Initiation and Termination of RSV Prophylaxis*

- Historical 2014-2017 CDC data from the 10 U.S. Department of Health and Human Services (HHS) regions, with the exception of Florida, shows RSV seasons commencing as early as September in some regions and ending as late as May in others.<sup>2-3</sup>
- Because 5 monthly Synagis doses at 15 mg/kg/dose will provide more than 6 months of serum palivizumab concentrations above the threshold for protection for most infants, administration of more than 5 monthly doses is not recommended within the continental U.S. Children who qualify for Synagis prophylaxis should receive the first dose at the onset of the RSV season. For qualifying infants born during the RSV season, fewer than 5 Synagis doses will be needed to provide protection until the RSV season ends in their region. A small number of sporadic RSV hospitalizations will occur before or after the main season in many areas of the U.S., but the greatest benefit from prophylaxis is derived during peak season and not when the incidence of RSV hospitalization is low.<sup>4-7</sup>
- Data from the Florida Department of Health (<http://www.floridahealth.gov/diseases-and-conditions/respiratory-syncytial-virus/>) may be used to determine the appropriate timing of Synagis prophylaxis across Florida’s regions where RSV seasons may begin at different times throughout the year. However, despite Florida’s variable region-specific RSV seasons, a maximum of 5 monthly Synagis doses should be adequate.<sup>4-7</sup>

*Appendix E: Dose Rounding Guidelines*

<b>Weight-based Dose Range</b>	<b>Vial Quantity Recommendation</b>
≤ 52.49 mg	1 vial of 50 mg/0.5 mL
52.5 mg – 104.99 mg	1 vial of 100 mg/1 mL
105 mg – 157.49 mg	1 vial of 50 mg/0.5 mL and 1 vial of 100 mg/1 mL
157.5 mg – 209.99 mg	2 vials of 100 mg/1 mL
210 mg – 262.49 mg	1 vial of 50 mg/0.5 mL and 2 vials of 100 mg/1 mL
262.5 mg – 314.99 mg	3 vials of 100 mg/1 mL

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
RSV prophylaxis in pediatric patients	15 mg/kg IM once a month	15 mg/kg/month; up to 5 doses per RSV season (1 extra dose if cardio-pulmonary bypass)

**VI. Product Availability**

Single-dose vials: 50 mg/0.5 mL, 100 mg/1 mL

**VII. References**

1. Synagis Prescribing Information. Gaithersburg, MD: MedImmune, LLC; May 2017. Available at <https://www.azpicentral.com/synagis/synagis.pdf#page=1>. Accessed February 17, 2021.
2. Respiratory syncytial virus infection (RSV): Trends and surveillance. Centers for Disease Control and Prevention website. Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Available at <http://www.cdc.gov/rsv/research/us-surveillance.html>. Page last reviewed: December 18, 2020. Accessed February 17, 2021.
3. Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory Syncytial Virus Seasonality — United States, 2014–2017. *MMWR Morb Mortal Wkly Rep* 2018;67:71–76. DOI: <http://dx.doi.org/10.15585/mmwr.mm6702a4>.
4. Red Book® 2018. Committee on Infectious Diseases; American Academy of Pediatrics; David W. Kimberlin, MD, FAAP; Michael T. Brady, MD, FAAP; Mary Anne Jackson, MD, FAAP; Sarah S. Long, MD, FAAP. Section 3: Respiratory Syncytial Virus. Available at <https://redbook.solutions.aap.org/Book.aspx?bookid=2205>. Accessed February 17, 2021.
5. Policy Statement: Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. *Pediatrics*. August 2014; 134(2): e415-20. doi: 10.1542/peds.2014-1665. Reaffirmed February 2019. Available online at <https://pediatrics.aappublications.org/content/134/2/415.full#sec-13>.
6. Technical Report: Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. *Pediatrics*. August 2014; 134(2): e620-38. doi: 10.1542/peds.2014-1666.
7. Errata: RSV Policy Statement: Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. American Academy of Pediatrics. *Pediatrics*. December 2014; 134(6): 1221.
8. Robbie, G, Zhao, L, Mondick, J, et al. Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody in Adults and Children. *Antimicrobial Agents and Chemotherapy*. Sept 2012; 56(9): 4927-4936.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Added “is Synagis prescribed for RSV prophylaxis” question to algorithm for clarity. No change in intent of criteria.	01.16	



<b>Reviews, Revisions, and Approvals</b>	<b>Date</b>	<b>P&amp;T Approval Date</b>
Updated template and disclaimer language		
Policy converted to new template. Prophylaxis for cardiac transplantation and profoundly immunocompromised infants added to criteria.	07.16	08.16
Safety information removed (hypersensitivity). Doses added.	07.17	08.17
2Q 2018 annual review: no significant changes; policies combined for Commercial and Medicaid; HIM line of business added; references reviewed and updated.	02.13.18	05.18
2Q 2019 annual review: RSV seasonal patterns are updated in Appendix D per the CDC and state health departments to indicate a season onset as early as September extending to as late as May (Florida seasonal information is updated to indicate possible year-round onset).	02.19.18	05.19
Ad hoc change made to clarify preterm/gestational age requirement in Section I.A.: diagnosis of preterm birth is updated to indicate diagnosis of preterm infant; defined as gestational age < 29 weeks is updated to indicate with gestational age < 29 weeks.	12.12.19	
2Q 2020 annual review: added appendix E: dose rounding guidelines; added reference to appendix E within criteria; revised HIM-Medical Benefit to HIM line of business; added that each dose of the Synagis prescription is written for RSV prophylaxis during current RSV season only; references reviewed and updated.	03.05.20	05.20
Seasonal coverage criteria are added to all indications; related AAP/CDC guidance is added to Appendix D.	05.01.20	08.20
2Q 2021 annual review: per prescribing information, added requirement for continued therapy that member will not reach 24 months of age at the start of RSV season; revised reference to HIM off-label use policy from HIM.PHAR.21 to HIM.PA.154; references reviewed and updated.	02.17.21	05.21

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health

plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2009 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise



published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.